SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
T-LGL is a heterogeneous disorder charcterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes (LGL) without a clearly identified cause.
(This neoplasm is reportable for cases diagnosed 2010 and later.) This code is used to describe T-cell large granular leukemia and chronic lymphoproliferative disorder of NK cells/chronic NK-cell large granular lymphocytic leukemia. This was formerly 9831/1 in ICD-O-3.
T-LGL leukemia involves the peripheral blood, bone marrow, liver, and spleen. Lymphadenopathy is very rare. This leukemia represents 3% of cases of mature lymphocytic leukemias. The disease is rare before 25 years of age and the majority of cases occur in those between ages 45-75. Severe neutropenia with or without anemia is frequent while thrombocytopenia is not. Moderate splenomegaly is the main physical finding. Rheumatoid arthritis, the presence of autoantibodies in the circulating immune complexes and hypergammaglobulinemia are common. The lymphoproliferation is typically indolent and non-progressive. Mortality is associated with cytopenias, especially neutropenia. Many patients receive no treatment, some receive aspirin, others corticosteroids, or they may receive chemotherapy in low doses. Some patients have a splenectomy.
Chronic lymphoproliferative disorder of NK cells predominantly involve the peripheral blood and bone marrow. The majority of patients are asymptomatic but some present with systemic symptoms and/or cytopenias (mainly neutropenia and anemia). Lymphadenopathy, hepatosplenomegaly, and cutaneous lesions are infrequent. This neoplasm may occur in association with other medical conditions such as solid and hematologic tumors, vasculitis, splenectomy, neuropathy, and autoimmune disorders. CLP-NK occurs predominantly in adults with a median age of 60 years. In the majority of patients the clinical course is indolent over a prolonged period. Disease progression with increasing lymphocytosis and worsening of cytopenia is observed in some cases.